Vol. 6, Issue 1, Part A (2024)

Background: Treating dyslipidemia, which is an important risk factor for life-threatening conditions such as heart attack, stroke, and other cardiovascular events, continues to be a dynamic topic. Moreover, an understanding of the appropriate treatment plan for dyslipidemia based on the patient’s condition is essential for practitioners across medical specialties. 
Methods: A questionnaire-based survey among 544 clinicians focusing on the prevalence, symptoms, causes, clinical characteristics, management of dyslipidemia, and the usage of rosuvastatin therapy in clinical practice will be useful to improve the clinical practice of lipid management. 
Results: About 96.3% of clinicians preferred rosuvastatin for patients with dyslipidemia. 50.2% reported excellent reviews and 54.8% agreed on the results of the HOPE-3 trial on rosuvastatin. Nearly one-third of clinicians preferred prescribing 10mg dose of rosuvastatin. Almost 89.2% did not feel pill burden and poor compliance as a big challenge in managing dyslipidemia. Only 57.5% of doctors preferred clopidogrel and 42.1% preferred aspirin as a combination drug to act with rosuvastatin. The combination of rosuvastatin + clopidogrel + aspirin was required only for 11-25% of their patients. 53.3% of doctors reported an improvement in overall outcomes by the combination of statin and dual antiplatelet therapy. For patients with high triglycerides, 82% of doctors surveyed preferred the fenofibrate + rosuvastatin combination. 
Conclusion: Despite the challenges in managing dyslipidemia, clinicians generally felt confident in their ability to address this condition effectively. This survey highlights the importance of tailored dyslipidemia management and the significance of evidence-based approaches to reduce cardiovascular risks.